HBM HLDGS LTD DL-000025 (6XY) - Total Liabilities
Based on the latest financial reports, HBM HLDGS LTD DL-000025 (6XY) has total liabilities worth €133.14 Million EUR (≈ $155.66 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore HBM HLDGS LTD DL-000025 net asset momentum to track the company's year-over-year net asset growth rate.
HBM HLDGS LTD DL-000025 - Total Liabilities Trend (2021–2025)
This chart illustrates how HBM HLDGS LTD DL-000025's total liabilities have evolved over time, based on quarterly financial data. See HBM HLDGS LTD DL-000025 free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
HBM HLDGS LTD DL-000025 Competitors by Total Liabilities
The table below lists competitors of HBM HLDGS LTD DL-000025 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ami Organics Limited
NSE:AMIORG
|
India | Rs2.29 Billion |
|
Akasha Wira International Tbk
JK:ADES
|
Indonesia | Rp516.28 Billion |
|
Eyebright Medical Technology Beijing Co Ltd
SHG:688050
|
China | CN¥1.64 Billion |
|
Beijing Bei Mo Gao Ke Friction Mate
SHE:002985
|
China | CN¥918.30 Million |
|
Metropolitan Kentjana Tbk
JK:MKPI
|
Indonesia | Rp2.24 Trillion |
|
SHANG.FOS.PHARM.GR.H YC 1
F:08HH
|
Germany | €59.30 Billion |
|
Lindsay Corporation
NYSE:LNN
|
USA | $329.92 Million |
|
Hangzhou Cogeneration Group Co Ltd
SHG:605011
|
China | CN¥1.24 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down HBM HLDGS LTD DL-000025's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see HBM HLDGS LTD DL-000025 market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.17 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.36 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.27 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how HBM HLDGS LTD DL-000025's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for HBM HLDGS LTD DL-000025 (2021–2025)
The table below shows the annual total liabilities of HBM HLDGS LTD DL-000025 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €133.14 Million ≈ $155.66 Million |
+46.37% |
| 2024-12-31 | €90.96 Million ≈ $106.34 Million |
-16.43% |
| 2023-12-31 | €108.85 Million ≈ $127.26 Million |
-22.04% |
| 2022-12-31 | €139.62 Million ≈ $163.23 Million |
+134.87% |
| 2021-12-31 | €59.45 Million ≈ $69.50 Million |
-- |
About HBM HLDGS LTD DL-000025
HBM Holdings Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of antibody therapeutics focusing on immunology and oncology in Mainland China, the United States, Europe, and internationally. It develops the Harbour Mice Platform, which generates human monoclonal antibodies in two heavy and two light chain H2L2 and heavy chain formats. The company i… Read more